Latest Information Update: 30 Mar 2007
At a glance
- Originator Molecular Targeting Technologies
- Mechanism of Action Cell membrane modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Myocardial infarction
Most Recent Events
- 21 Nov 2001 Preclinical development for Myocardial infarction in USA (Unknown route)